Patents by Inventor Eduardo Munoz

Eduardo Munoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220352501
    Abstract: A novel biomass derived catalyst doped porous carbon material and efficient methods to produce it. The doped porous carbon material can be used as a host to generate several materials with a higher performance than exhibited by previous materials. The host material performance enhancement is due to ability to control the amount of doping material, material structure, surface property, and pore size, as well as a high surface area and large pore volume allowing for high sulfur loading. In addition, the hierarchical structure of the porous composites allows an increased in energy density and long cycle life.
    Type: Application
    Filed: February 25, 2022
    Publication date: November 3, 2022
    Applicant: Xponential Battery Materials B.V.
    Inventors: Junbing Yang, Eduardo Munoz
  • Publication number: 20220226259
    Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.
    Type: Application
    Filed: April 29, 2020
    Publication date: July 21, 2022
    Inventors: Jon PEÑARANDO SÁEZ, Juan Diego UNCITI BROCTETA, Eduardo MUÑOZ BLANCO
  • Publication number: 20220223338
    Abstract: A transformer assembly includes: a first switching apparatus configured to be electrically connected to a first segment of a transformer loop; a second switching apparatus configured to be electrically connected to a second segment of the transformer loop; and a transformer including: a first coil electrically connected to the first switching apparatus and the second switching apparatus; and a second coil electrically connected to an output configured to electrically connect to a load.
    Type: Application
    Filed: December 8, 2021
    Publication date: July 14, 2022
    Inventors: Samuel T. Reed, Steven Howard Buehler, Eduardo Muñoz Sampedro
  • Publication number: 20220184003
    Abstract: Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the same for use in the treatment of various conditions, and diseases, including diseases associated with demyelination.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 16, 2022
    Applicant: EMERALD HEALTH PHARMACEUTICALS INC
    Inventors: Alain ROLLAND, Eduardo Munoz BLANCO
  • Publication number: 20220041538
    Abstract: A compound of formula I or a pharmaceutical salt thereof of formula II, as well as a process to obtain said compound and a process to obtain said salt. Additionally, disclosed is the use of said compound of formula I or said pharmaceutical salt thereof of formula II as a medicament, in particular as a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, for use in the treatment or prevention of a disease responsive to PPAR? agonists. Also disclosed is a pharmaceutical composition comprising said compound or said salt, as well as a method of treating or preventing a disease with said compound of formula I or said salt thereof of formula II, or with a composition comprising said compound or said salt.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 10, 2022
    Applicant: EMERALD HEALTH PHARMACEUTICALS INC
    Inventors: Eduardo MUÑOZ BLANCO, Giovanni APPENDINO
  • Publication number: 20220026426
    Abstract: Described are assays, associated assay kits, and associated methods for diagnosing an infection in a subject. The assay includes a first binding molecule that specifically binds an inflammatory marker (i.e., neutrophil gelatinase-associated lipocalin (NGAL) homodimer) in a sample taken from the subject, and a second binding molecule that binds a marker indicative of the presence of a pathogen in the sample. The assay and methods are for the diagnosis of peritonitis in peritoneal dialysis patients.
    Type: Application
    Filed: July 23, 2021
    Publication date: January 27, 2022
    Inventors: Tao Jiang, YongSheng Ji, Jesus Eduardo Muñoz-Silva, Fangfang Huang, Changna Wang
  • Publication number: 20210317070
    Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
    Type: Application
    Filed: February 16, 2021
    Publication date: October 14, 2021
    Inventors: Eduardo MUÑOZ BLANCO, Carmen María NAVARRETE RUEDA, Cristina CRUZ TENO, María Luz BELLIDO CABELLO DE ALBA
  • Patent number: 10919843
    Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: February 16, 2021
    Assignee: Emerald Health Pharmaceuticals Inc.
    Inventors: Eduardo Muñoz Blanco, Carmen María Navarrete Rueda, Cristina Cruz Teno, María Luz Bellido Cabello De Alba
  • Patent number: 10766855
    Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: September 8, 2020
    Assignee: VIVACELL BIOTECHNOLOGY ESPAÑA, S.L.
    Inventors: Eduardo Munoz Blanco, Alberto Minassi, Maria Luz Bellido Cabello De Alba, Giovanni Appendino
  • Publication number: 20200087247
    Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
    Type: Application
    Filed: March 29, 2017
    Publication date: March 19, 2020
    Inventors: Eduardo MUÑOZ BLANCO, Carmen María NAVARRETE RUEDA, Cristina CRUZ TENO, María Luz BELLIDO CABELLO DE ALBA
  • Publication number: 20190367447
    Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.
    Type: Application
    Filed: October 3, 2017
    Publication date: December 5, 2019
    Inventors: Eduardo MUNOZ BLANCO, Alberto MINASSI, Maria Luz BELLIDO CABELLO DE ALBA, Giovanni APPENDINO
  • Patent number: 10339658
    Abstract: A method for making a segmentation in the sorted sequence of data (100), that comprises arranging a sequential stream of sorted input data (10), where the data are arranged in matrices (frames), in this case by way of a preferred example as a sequence of images for image analysis (20), and that delivers a sequential stream of sorted output data (30), where the sorted output data are arranged in sorted matrices.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: July 2, 2019
    Assignee: Oculus Machina S.P.A.
    Inventor: César Eduardo Muñoz Parraguez
  • Publication number: 20190188859
    Abstract: A method for making a segmentation in the sorted sequence of data (100), that comprises arranging a sequential stream of sorted input data (10), where the data are arranged in matrices (frames), in this case by way of a preferred example as a sequence of images for image analysis (20), and that delivers a sequential stream of sorted output data (30), where the sorted output data are arranged in sorted matrices.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 20, 2019
    Inventor: César Eduardo Muñoz Parraguez
  • Patent number: 9802880
    Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: October 31, 2017
    Inventors: Giovanni Appendino, María Luz Bellido Cabello De Alba, Eduardo Muñoz Blanco
  • Publication number: 20170247308
    Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Application
    Filed: February 12, 2015
    Publication date: August 31, 2017
    Applicant: VIVACELL BIOTECHNOLOGY ESPAÑA S.L.
    Inventors: Giovanni APPENDINO, María Luz BELLIDO CABELLO DE ALBA, Eduardo MUÑOZ BLANCO
  • Patent number: 9732446
    Abstract: The present invention relates to a thermally-resistant woven fabric and/or multiple ply fabric sheet for use as single or outer layer of protective garments, of the type comprising an inside fabric layer and an outside fabric layer joined together by an array of connecting lines. The woven fabric and/or multiple ply fabric sheet comprise yarns, wherein said yarn comprises i) meta-aramid ii) from about 5 to 10 weight % of polyamide and iii) at least 2 weight % of antistatic fibers, the weight % being based on the total weight of the yarn.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: August 15, 2017
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Frederique Favier, Eduardo Munoz, Yves Bader
  • Patent number: 9701618
    Abstract: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: July 11, 2017
    Inventors: Giovanni Appendino, María Luz Bellido Cabello De Alba, Eduardo Muñoz Blanco
  • Publication number: 20170044092
    Abstract: The present invention relates to novel cannabidiol quinone derivatives of formula (I) (I) wherein R is the carbon atom of a, linear or branched group, represented by: alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl groups; or wherein R is the nitrogen atom of a, linear or branched group represented by: alkylamine, arylamine, alkenylamine or alkynylamine groups. The invention also relates to the use of any of the compounds of formula (I) as medicamentsin therapy, particularly for treating diseases and conditions responsive to PPARg modulation due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.
    Type: Application
    Filed: April 16, 2014
    Publication date: February 16, 2017
    Inventors: Giovanni APPENDINO, María Luz BELLIDO CABELLO DE ALBA, Eduardo MUÑOZ BLANCO
  • Patent number: 9416083
    Abstract: The present invention relates to a new method for isolating ingenol (C20H28O5) from mixtures of diterpenoid esters and ingenol esters in a single step. Ingenol isolated by means of this method can be used as a precursor for the synthesis of biologically active ingenol derivatives, such as ingenol-3-angelate and ingenol-3-tigliate.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: August 16, 2016
    Assignee: INDENA S.P.A.
    Inventors: Maria Luz Bellido Cabello De Alba, Giovanni Appendino, Alberto Pagani, Eduardo Munoz Blanco
  • Patent number: 9291185
    Abstract: Direct connection between a tube and a flat element by means of a connector preferably formed by stamping on the tube itself, which enables joining the latter to the flat element, without auxiliary elements, by nest-like insertion of same into the flat element and subsequent attachment by means of screws, rivets, bolts, pins or other elements.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: March 22, 2016
    Assignee: Europea De Construcciones Metalicas, S.A.
    Inventors: Eduardo Muñoz Fernandez, Maximiliano Carrasco Gimena, José Ignacio Parra Fernández-Mota, Luis Garrido Delgado